期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 22, 期 2, 页码 640-645出版社
WILEY
DOI: 10.1111/ajt.16843
关键词
health services and outcomes research; infection and infectious agents-viral; infectious disease; kidney transplantation; nephrology; patient survival
资金
- Warren Alpert Medical School of Brown University Summer Assistantship Program
It has been shown that passive immunization with anti-spike monoclonal antibodies (mAbs) may greatly benefit organ transplant recipients in mounting an immune response to COVID-19. The study found that mAb therapy significantly decreased hospitalizations or emergency room visits among kidney transplant recipients with COVID-19, with potential disparities in treatment access and outcomes based on patient race and ethnicity.
Organ transplant recipients may not mount an adequate immune response to COVID-19 infection and therefore may benefit greatly from passive immunization with anti-spike monoclonal antibodies (mAbs), which have been shown to decrease hospitalization rates in the general outpatient population. We evaluated the efficacy of mAb therapy in decreasing hospitalizations or emergency room (ER) visits among kidney transplant recipients (KTR) with COVID-19. We identified KTR with COVID-19 between March 1, 2020 and April 30, 2021. Patients were excluded if they had multi-organ transplant or hospital-acquired COVID-19. We studied 95 KTR; 20 received mAb. mAb administration was associated with a significant decrease in hospitalizations or ER visits (15% vs. 76%, p < 0.001). This association remained significant after adjustment for potential confounders, and analysis of mAb administration as a time-dependent variable, with day of symptom onset as day 1 (adjusted HR 0.216, p = 0.04). Black or Hispanic patients were less likely to receive mAb and more likely to be admitted to the hospital or visit the ER. In our KTR population, mAb therapy for COVID-19 may have helped decrease hospitalizations and ER visits. Healthcare inequities, including access to investigational treatments, have been exacerbated by the COVID-19 pandemic. Antiviral mAbs are a promising therapeutic modality, especially for immunocompromised patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据